Live tape
Top 8, mentions 7d10,375TSLA2,414 mentions▲ +0.06SPCX1,882 mentions▲ +0.08GOOGL1,298 mentions▲ +0.04CRWV1,186 mentions▲ +0.04NVDA1,045 mentions▲ +0.07QQQ1,009 mentions▲ +0.05META776 mentions▲ +0.05NBIS765 mentions▲ +0.07

Equity · Healthcare

ENTA

NASDAQ

Enanta Pharmaceuticals (ENTA)

$13.74 +5.69% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close)
Price · Chart

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for ENTA to draw a line in its place.

Track this symbol on TradingView TradingView chart
Market cap $400.2M
52-week range $6.50 – $16.85
Avg volume 43.8K

as of Jul 17, 2026

Enanta Pharmaceuticals (ENTA) insider trades

SEC Form 4 · last 90 days · newest Form 4 filing 8 Aug 2026

In the 90 days to 21 Oct 2026, no Enanta Pharmaceuticals insider bought or sold shares on the open market; the 1 Form 4 filing in that window was a grant, exercise, tax withholding or transfer (SEC Form 4).

Open-market buys 0
Open-market sells 0
Non-trade filings 1

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
08 Aug 2026 Rottinghaus Scott T. Chief Medical Officer Tax withheld 1,467 $20K

Enanta Pharmaceuticals (ENTA) reported financials

SEC EDGAR XBRL SEC EDGAR

Enanta Pharmaceuticals reported revenue of $65.3M for the fiscal year ended 30 Sep 2025. Net income over the same period was −$81.9M.

Figure Reported Period
Revenue $65.3M 30 Sep 2025 fiscal year
Net income −$81.9M 30 Sep 2025 fiscal year
Diluted EPS −$3.84 30 Sep 2025 fiscal year
Total assets $296.9M 30 Jun 2026 at period end
Total equity $101.1M 30 Jun 2026 at period end

Enanta Pharmaceuticals (ENTA) earnings

SEC EDGAR

Enanta Pharmaceuticals last reported earnings on 30 Jun 2026 for Q3 2026, with EPS of −$0.67; no next date is announced in SEC filings yet.

Date Period EPS Revenue
30 Jun 2026 Q3 2026 −$0.67 —
31 Mar 2026 Q2 2026 −$0.45 —
31 Dec 2025 Q1 2026 −$0.42 —
30 Sep 2025 FY 2025 −$3.84 —
30 Jun 2025 Q3 2025 −$0.85 —
31 Mar 2025 Q2 2025 −$1.06 —
31 Dec 2024 Q1 2024 −$1.05 —
30 Sep 2024 FY 2024 −$5.48 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

Enanta Pharmaceuticals (ENTA) institutional holders (13F)

SEC Form 13F SEC EDGAR

8 of the 45 institutional funds we track reported a Enanta Pharmaceuticals position for the quarter ended 30 Jun 2026 — a combined $25.7M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Millennium Management Trimmed −27.0% shares 643,967 $9.4M
Renaissance Technologies Held (±25%) −16.2% shares 557,600 $8.1M
AQR Capital Management Held (±25%) −18.0% shares 256,870 $3.7M
Marshall Wace Trimmed −37.2% shares 131,995 $1.9M
Two Sigma Investments Trimmed −73.4% shares 71,162 $1.0M
Citadel Advisors Trimmed −80.6% shares 50,844 $741K
D. E. Shaw & Co. Trimmed −51.3% shares 34,539 $504K
Balyasny Asset Management New position 14,915 $217K
Man Group Exited
Tudor Investment Corp Exited

Enanta Pharmaceuticals (ENTA) fails-to-deliver

SEC CNS data SEC

On 23 Sep 2026, 5,934 shares of Enanta Pharmaceuticals failed to deliver (about $74K).

Settlement date Shares failed Notional % of shares out
23 Sep 2026 5,934 $74K 0.020%

Congressional trades in Enanta Pharmaceuticals (ENTA)

STOCK Act disclosures House disclosures

The most recent congressional trade disclosed in Enanta Pharmaceuticals is a sale by Daniel S. Goldman (house, NY), dated 12 Jul 2023.

Date Member Type Amount
12 Jul 2023 filed 13 Aug 2023 Daniel S. Goldman house · Democrat–NY Sale $1K–$15K

Enanta Pharmaceuticals (ENTA): frequently asked questions

From live data

Have Enanta Pharmaceuticals insiders bought or sold shares recently?

In the 90 days to 21 Oct 2026, no Enanta Pharmaceuticals insider bought or sold shares on the open market; the 1 Form 4 filing in that window was a grant, exercise, tax withholding or transfer (SEC Form 4).

How many institutions hold Enanta Pharmaceuticals?

8 of the 45 institutional funds we track reported a Enanta Pharmaceuticals position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.

Has Enanta Pharmaceuticals had fails-to-deliver recently?

Yes. The most recent SEC fails-to-deliver record for Enanta Pharmaceuticals is dated 23 Sep 2026, when 5,934 shares failed to deliver.

When did Enanta Pharmaceuticals last report earnings?

Enanta Pharmaceuticals last reported earnings on 30 Jun 2026 for Q3 2026, with EPS of −$0.67; no next date is announced in SEC filings yet.

What exchange is Enanta Pharmaceuticals listed on?

Enanta Pharmaceuticals trades on NASDAQ under the ticker ENTA.

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. House disclosuresU.S. House of Representatives financial disclosures
  7. SEC EDGARValuation computed from SEC EDGAR filings